SCI & TECH● LOW1h ago · Oct 26, 2026, 3:01 PM
Acumen targets 30% iADRS slowing as Phase II ALTITUDE-AD data due in November
Seeking Alpha Tech · global
Acumen aims for a 30% slowing in iADRS, with Phase II ALTITUDE-AD data expected in November. This indicates a key milestone for a pharmaceutical company's clinical trial.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH17m agoYour brain’s unexpected ability to regenerate and how to harness itNew ScientistSCI & TECH17m agoPredatory amphibians swam the seas 237 million years agoNew ScientistSCI & TECH18m agoDelhi teenager’s Project Sadak logs 2,927 road complaints across Delhi, Mumbai, Bengaluru; tracks 190 repairsThe HinduSCI & TECH26m agoAnthropic files for IPO as it competes for dominance in AI arms raceCBS News